NeonMind Announces Organizational Changes
May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today
Investor Presentation
View our latest Investor Presentation to find the most recent investor-related information
Latest News
NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic
April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE
NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic
April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE /
NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
April 11, 2021 8:00am EDT Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across
Email Alerts
Sign up today and receive company updates straight to your inbox.
Investor Presentation
Company Overview
NeonMind is an integrated psychedelic drug development and wellness company focused on therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. NeonMind has two operating divisions, a pharmaceutical division engaged in drug development research for the potential therapeutic uses of psychedelic compounds, and a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
Investor Contact Information
Company
NeonMind Biosciences Inc.
5 – 519 Dundas St. W.
Suite #511
Oakville, ON L6M 5K3
Canada
Investor Relations
T: +1 (705) 710-NEON /
+1 (705) 710-6366
Transfer Agent
Endeavor Trust Corporation
T: 604-559-8908
david@endeavortrust.com
English